Sergey A. Makarov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sergey A. Makarov has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Anna A. Pilipovich
Sechenov First Moscow State Medical University (Sechenov University)
9 shared publications - Olga V. Vorob’еVa
I.M. Sechenov First Moscow State Medical University (Sechenov University)
9 shared publications - Aleksandra L. Guseva
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
5 shared publications - Vadim Petrovich Pavlov
V.A. Nasonova Research Institute of Rheumatology
3 shared publications - Andrey V. Kuchuk
Peoples' Friendship University of Russia
2 shared publications - Natalya N. Shindryaeva
Sechenov First Moscow State Medical University, Moscow, Russia
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Parkinson's Disease
- Vol. 2026 (1) , 9026870
Quantitative Evaluation of Respiratory Dysfunction and Its Relationships With Parkinson’s Disease Symptoms
Respiratory disorders significantly impair functional baseline and quality of life (QoL) in Parkinson’s disease (PD). This cross‐sectional study aimed to evaluate spirographic lung function parameters in PD and determine their relationships with motor and nonmotor symptoms, QoL, and dopaminergic therapy. Spirometric parameters were recorded in 57 outpatients with PD and 10 healthy controls. PD patients underwent clinical assessments using UPDRS Parts II and III, Schwab and England scale, PDQ‐39, and PFS‐16. Spirometric analysis revealed significant decreases in VC %pred in PD patients versus controls, and in FVC %pred in PD Stage III versus PD Stage II. Decreased lung function correlated with H&Y stage (VC, FVC, FEV 1 ) and showed inverse correlations with UPDRS Parts II and III scores, most pronounced for axial‐locomotor impairments (posturing, gait, stability, arising from chair) and bradykinesia. PFS‐16 fatigue index inversely correlated with FEV 1 and PEF. Worse QoL (PDQ‐39 summary index, emotional well‐being, and cognition domains) was primarily coupled with decreased expiratory flow rates (FEV 1 , PEF). Untreated PD patients exhibited significantly lower FVC%pred, FEV 1 %pred, FEF 75 %pred, and Tiffeneau index than those on dopaminergic therapy. This study demonstrates the presence of respiratory dysfunction in PD Stages II and III and its negative association with QoL. The results highlight the relationship between lung function decline and overall PD progression, with the strongest associations revealing the most significant contribution of postural abnormalities, bradykinesia, and pathological fatigue. Furthermore, the obtained data suggest a potential compensating role of dopaminergic therapy.
- 1 January 2026
- Published by Wiley in Parkinson's Disease
- Vol. 2026 (1) , 9026870
Open AccessQuantitative Evaluation of Respiratory Dysfunction and Its Relationships With Parkinson’s Disease Symptoms
Respiratory disorders significantly impair functional baseline and quality of life (QoL) in Parkinson’s disease (PD). This cross‐sectional study aimed to evaluate spirographic lung function parameters in PD and determine their relationships with motor and nonmotor symptoms, QoL, and dopaminergic therapy. Spirometric parameters were recorded in 57 outpatients with PD and 10 healthy controls. PD patients underwent clinical assessments using UPDRS Parts II and III, Schwab and England scale, PDQ‐39, and PFS‐16. Spirometric analysis revealed significant decreases in VC %pred in PD patients versus controls, and in FVC %pred in PD Stage III versus PD Stage II. Decreased lung function correlated with H&Y stage (VC, FVC, FEV 1 ) and showed inverse correlations with UPDRS Parts II and III scores, most pronounced for axial‐locomotor impairments (posturing, gait, stability, arising from chair) and bradykinesia. PFS‐16 fatigue index inversely correlated with FEV 1 and PEF. Worse QoL (PDQ‐39 summary index, emotional well‐being, and cognition domains) was primarily coupled with decreased expiratory flow rates (FEV 1 , PEF). Untreated PD patients exhibited significantly lower FVC%pred, FEV 1 %pred, FEF 75 %pred, and Tiffeneau index than those on dopaminergic therapy. This study demonstrates the presence of respiratory dysfunction in PD Stages II and III and its negative association with QoL. The results highlight the relationship between lung function decline and overall PD progression, with the strongest associations revealing the most significant contribution of postural abnormalities, bradykinesia, and pathological fatigue. Furthermore, the obtained data suggest a potential compensating role of dopaminergic therapy.
- Open Access
- 24 June 2025
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 17 (3) , 33–40
Autonomic cardiovascular dysregulation and other non-motor manifestations of Parkinson’s disease
Most patients with Parkinson’s disease (PD) experience autonomic cardiovascular dysfunction (insufficiency), which, together with other nonmotor manifestations, negatively affects quality of life and disease progression.Objective: to assess the relationship between autonomic cardiovascular dysfunction and other non-motor symptoms of PD.Material and methods. A total of 252 patients with PD Hoehn and Yahr stages I–III were examined. The evaluation included: a questionnaire aimed at identifying symptoms of orthostatic intolerance (OI), orthostatic test, evaluation using the Unified Parkinson’s Disease Rating Scale (UPDRS I–IV), the Schwab and England Activities of Daily Living Scale (Sch&En), the Mini-Mental State Examination (MMSE), the Non-Motor Symptoms Questionnaire (NMSQ), the Beck Depression Inventory, the Spielberger State-Trait Anxiety Inventory, the Glasgow Dyspepsia Severity Score (GDSS), the Gastrointestinal Symptom Rating Scale (GSRS), the Bristol Stool Form Scale (BSFS), and the International Prostate Symptom Score (IPSS). A subset of patients (n=31) underwent heart rate variability (HRV) assessment.Results. Among patients with OI symptoms (35.3% of all participants) we found the worst non-motor outcomes UPDRS I (pConclusion. The data indicate that one-third of stages I–III PD patients exhibit clinical signs of autonomic dysregulation affecting the cardiovascular system, gastrointestinal tract, and bladder. These are closely associated with other non-motor symptoms of PD, forming a unified neurodegenerative process involving both central and peripheral components of the nervous system. We propose that OI symptoms may serve as clinical markers of emerging widespread autonomic failure.
- 24 June 2025
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 17 (3) , 33–40
Open AccessAutonomic cardiovascular dysregulation and other non-motor manifestations of Parkinson’s disease
Most patients with Parkinson’s disease (PD) experience autonomic cardiovascular dysfunction (insufficiency), which, together with other nonmotor manifestations, negatively affects quality of life and disease progression.Objective: to assess the relationship between autonomic cardiovascular dysfunction and other non-motor symptoms of PD.Material and methods. A total of 252 patients with PD Hoehn and Yahr stages I–III were examined. The evaluation included: a questionnaire aimed at identifying symptoms of orthostatic intolerance (OI), orthostatic test, evaluation using the Unified Parkinson’s Disease Rating Scale (UPDRS I–IV), the Schwab and England Activities of Daily Living Scale (Sch&En), the Mini-Mental State Examination (MMSE), the Non-Motor Symptoms Questionnaire (NMSQ), the Beck Depression Inventory, the Spielberger State-Trait Anxiety Inventory, the Glasgow Dyspepsia Severity Score (GDSS), the Gastrointestinal Symptom Rating Scale (GSRS), the Bristol Stool Form Scale (BSFS), and the International Prostate Symptom Score (IPSS). A subset of patients (n=31) underwent heart rate variability (HRV) assessment.Results. Among patients with OI symptoms (35.3% of all participants) we found the worst non-motor outcomes UPDRS I (pConclusion. The data indicate that one-third of stages I–III PD patients exhibit clinical signs of autonomic dysregulation affecting the cardiovascular system, gastrointestinal tract, and bladder. These are closely associated with other non-motor symptoms of PD, forming a unified neurodegenerative process involving both central and peripheral components of the nervous system. We propose that OI symptoms may serve as clinical markers of emerging widespread autonomic failure.
- 12 May 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (4) , 59-67
Correlation of motor symptoms and cardiovascular dysfunction in Parkinson’s disease
Objective. Assessment of cardiovascular (CV) dysfunction, its association with motor symptoms of Parkinson’s disease (PD) and dopaminergic therapy. Material and methods. The study included 252 patients with Hoehn and Yahr stage I—III PD. All patients were assessed using a survey of symptoms of orthostatic intolerance (OI), an orthostatic test, UPDRS II—IV, a Sch&En daily activity score, and a Mini-Mental State Examination (MMSE). A heart rate variability (HRV) test was performed on 31 patients and 10 control subjects of comparable age. Results. OI symptoms were detected in 35.3% of patients, orthostatic hypotension in 5.8%, and lying hypertension in 34%. The HRV indices (SDNN, TP, VLF, and LF) were decreased in all patients versus the controls (p<0.0001); no normal increase in sympathetic effects occurred with the orthostatic test. The PD stage was associated with OI symptoms (p=0.003), a decrease in the total HRV power (rS=–0.357; p=0.049), an increase in lying hypertension and heart rate, and a decrease in changes in heart rate during the orthostatic test. Patients with OI symptoms had longer PD history and worse Sch&En and UPDRS scores (hypokinesia, posture, resistance, dyskinesia scores). Significant negative correlations of HRV were identified with the same motor indices: UPDRS II and III, impaired gait, posture, stiffness, and rigidity. Resting tremor or action tremor had no association with HRV and OI. The use of dopaminergic drugs (levodopa, amantadines, dopamine receptor agonists) was associated with lower systemic blood pressure and OI symptoms but did not aggravate orthostatic responses and HRV. Conclusion. Obtained data indicate the presence in patients with the initial stages of PD of autonomic CV dysfunction, closely related to the motor (especially walking and postural balance) symptoms of PD by a single neurodegenerative process covering both central and peripheral structures of the autonomic nervous system.
- 12 May 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (4) , 59-67
Correlation of motor symptoms and cardiovascular dysfunction in Parkinson’s disease
Objective. Assessment of cardiovascular (CV) dysfunction, its association with motor symptoms of Parkinson’s disease (PD) and dopaminergic therapy. Material and methods. The study included 252 patients with Hoehn and Yahr stage I—III PD. All patients were assessed using a survey of symptoms of orthostatic intolerance (OI), an orthostatic test, UPDRS II—IV, a Sch&En daily activity score, and a Mini-Mental State Examination (MMSE). A heart rate variability (HRV) test was performed on 31 patients and 10 control subjects of comparable age. Results. OI symptoms were detected in 35.3% of patients, orthostatic hypotension in 5.8%, and lying hypertension in 34%. The HRV indices (SDNN, TP, VLF, and LF) were decreased in all patients versus the controls (p<0.0001); no normal increase in sympathetic effects occurred with the orthostatic test. The PD stage was associated with OI symptoms (p=0.003), a decrease in the total HRV power (rS=–0.357; p=0.049), an increase in lying hypertension and heart rate, and a decrease in changes in heart rate during the orthostatic test. Patients with OI symptoms had longer PD history and worse Sch&En and UPDRS scores (hypokinesia, posture, resistance, dyskinesia scores). Significant negative correlations of HRV were identified with the same motor indices: UPDRS II and III, impaired gait, posture, stiffness, and rigidity. Resting tremor or action tremor had no association with HRV and OI. The use of dopaminergic drugs (levodopa, amantadines, dopamine receptor agonists) was associated with lower systemic blood pressure and OI symptoms but did not aggravate orthostatic responses and HRV. Conclusion. Obtained data indicate the presence in patients with the initial stages of PD of autonomic CV dysfunction, closely related to the motor (especially walking and postural balance) symptoms of PD by a single neurodegenerative process covering both central and peripheral structures of the autonomic nervous system.
- 24 March 2025
- Published by Alfmed LLC in Medical alphabet
- No. 2,p. 7-13
Algorithm for diagnosis and treatment of dizziness. Assistance for practicing physicians
Objective. The aim of this article is to systematize the main information on the most common causes of dizziness and to present a diagnostic and treatment algorithm that can be used by doctors from various specialties. Materials and Methods. The article is presented as a narrative review and includes an analysis of contemporary scientific publications on dizziness. Results. Data on the most common causes of dizziness have been systematized. A diagnostic and treatment algorithm for dizziness is presented, which can be used by healthcare practitioners. Practical recommendations are provided for the examination and medical history collection of patients with dizziness. Information on a multimodal approach to patient management is also presented. Conclusions. The use of a clear algorithm optimizes the diagnosis and treatment of dizziness, thereby improving the quality of medical care.
- 24 March 2025
- Published by Alfmed LLC in Medical alphabet
- No. 2,p. 7-13
Algorithm for diagnosis and treatment of dizziness. Assistance for practicing physicians
Objective. The aim of this article is to systematize the main information on the most common causes of dizziness and to present a diagnostic and treatment algorithm that can be used by doctors from various specialties. Materials and Methods. The article is presented as a narrative review and includes an analysis of contemporary scientific publications on dizziness. Results. Data on the most common causes of dizziness have been systematized. A diagnostic and treatment algorithm for dizziness is presented, which can be used by healthcare practitioners. Practical recommendations are provided for the examination and medical history collection of patients with dizziness. Information on a multimodal approach to patient management is also presented. Conclusions. The use of a clear algorithm optimizes the diagnosis and treatment of dizziness, thereby improving the quality of medical care.
- 13 March 2025
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 23 (1)
Transcranial magnetic stimulation in visual snow syndrome and functional disorders of visual perception
Visual snow syndrome (VSS) is one of the diseases of visual perception. It was first included in the International Classification of Headache disorders (3rd edition, 2018) as possible complication of migraine with aura. Despite the awareness of specialists regarding transcranial magnetic stimulation (TMS) in migraine, the issues of TMS for VSS remain insufficiently studied. At the same time, TMS as a therapeutic and diagnostic tool aimed at modulating the cortical bioelectrical activity can contribute to better understanding of pathophysiological mechanisms of VSS and correction of appropriate symptoms. The authors discuss TMS for visual perception disorders.
- 13 March 2025
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 23 (1)
Transcranial magnetic stimulation in visual snow syndrome and functional disorders of visual perception
Visual snow syndrome (VSS) is one of the diseases of visual perception. It was first included in the International Classification of Headache disorders (3rd edition, 2018) as possible complication of migraine with aura. Despite the awareness of specialists regarding transcranial magnetic stimulation (TMS) in migraine, the issues of TMS for VSS remain insufficiently studied. At the same time, TMS as a therapeutic and diagnostic tool aimed at modulating the cortical bioelectrical activity can contribute to better understanding of pathophysiological mechanisms of VSS and correction of appropriate symptoms. The authors discuss TMS for visual perception disorders.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (11) , 91-99
Bladder dysfunction in patients with stages I—III of Parkinson’s disease
Objective. To evaluate bladder dysfunction (BD) and its relationship with Parkinson’s disease (PD) symptoms and dopaminergic therapy. Material and methods. One hundred and thirteen patients with PD of I—III H&Y stages were examined using the following scales: IPSS, including irritative and obstructive symptom indices, UPDRS I—IV, Sch&En, PDQ-39, BDI, STAI, PFS-16, GDSS, GSRS, MMSE, FAB and NMSQ. Results. Most of the patients (89.4%) had BD according to IPSS (Me=6.0 [3.0—13.0]), all of them showed irritative disorders, which were combined with obstructive ones in 61%. BD did not depend on sex, stage and duration of PD. IPSS scores correlated with age (rS=0.307), Sch&En (rS=–0.210) and PDQ-39 (rS=0.460), total UPDRS score (rS=0.296) and subscales I—IV scores, postural stability, and non-motor disorders (depression, anxiety, fatigue, frontal dysfunction, and gastrointestinal and orthostatic symptoms). No significant effect of dopaminergic therapy on BD severity was found. BD occurrence predictors according to regression analysis are (R2=0.420) BDI, FAB and male sex. An analysis of obstructive symptoms index in the general group and separately for women showed many correlations with motor PD symptoms (hypokinesia, rigidity, and off-periods) meanwhile the irritative index had practically no such correlations. Conclusions. BD is present in the majority of PD patients and significantly reduces the quality of life already in the early stages of PD; BD predictors are depression, frontal dysfunction and male sex. Both obstructive and evacuation dysfunctions are detected in men and women. The obstructive dysfunction relations with a wide range of motor and non-motor PD symptoms indicate that neurodegenerative process is involved in its development.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (11) , 91-99
Bladder dysfunction in patients with stages I—III of Parkinson’s disease
Objective. To evaluate bladder dysfunction (BD) and its relationship with Parkinson’s disease (PD) symptoms and dopaminergic therapy. Material and methods. One hundred and thirteen patients with PD of I—III H&Y stages were examined using the following scales: IPSS, including irritative and obstructive symptom indices, UPDRS I—IV, Sch&En, PDQ-39, BDI, STAI, PFS-16, GDSS, GSRS, MMSE, FAB and NMSQ. Results. Most of the patients (89.4%) had BD according to IPSS (Me=6.0 [3.0—13.0]), all of them showed irritative disorders, which were combined with obstructive ones in 61%. BD did not depend on sex, stage and duration of PD. IPSS scores correlated with age (rS=0.307), Sch&En (rS=–0.210) and PDQ-39 (rS=0.460), total UPDRS score (rS=0.296) and subscales I—IV scores, postural stability, and non-motor disorders (depression, anxiety, fatigue, frontal dysfunction, and gastrointestinal and orthostatic symptoms). No significant effect of dopaminergic therapy on BD severity was found. BD occurrence predictors according to regression analysis are (R2=0.420) BDI, FAB and male sex. An analysis of obstructive symptoms index in the general group and separately for women showed many correlations with motor PD symptoms (hypokinesia, rigidity, and off-periods) meanwhile the irritative index had practically no such correlations. Conclusions. BD is present in the majority of PD patients and significantly reduces the quality of life already in the early stages of PD; BD predictors are depression, frontal dysfunction and male sex. Both obstructive and evacuation dysfunctions are detected in men and women. The obstructive dysfunction relations with a wide range of motor and non-motor PD symptoms indicate that neurodegenerative process is involved in its development.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Bulletin of Otorhinolaryngology
- Vol. 89 (5) , 4-9
Tinnitus features and masking in patients with normal hearing and with high frequency hearing loss
Objective. To access tinnitus features and effectiveness of its masking in relation to sensorineural hearing loss (SHL), gender, age, affected side and tinnitus pitch. Material and methods. 53 patients (32 (60.4%) females and 21 (39.6%) males) aged 20 to 46 years with unilateral chronic tinnitus without any external or middle ear pathology were enrolled in the study. All patients underwent pure tone audiometry, evaluating SHL, tinnitus pitch and tinnitus masking. Pure-tone thresholds were measured at all standard frequencies from 0.25 to 8 kHz, and at 10 kHz, 12.5 kHz, 14 kHz, 16 kHz, and 20 kHz. Results. Normal hearing at the studied frequencies was observed in 24 patients, and 29 patients were found to have SHL. Patients with high-frequency SHL identified tinnitus pitch more often identified tinnitus pitch compared to those with normal hearing (75.9% vs. 45%, respectively; p=0.02). Tinnitus pitch in patients with normal hearing was 8 (6-13) kHz, whereas in all patients with SHL tinnitus pitch was always located in the range of maximum hearing loss and reached 10 (8-12) kHz. The mean tinnitus pitch, which was successfully masked, was 8 Hz, and tinnitus pitches with mean value above 12 kHz were not associated with effective masking (p=0.04). No statistically significant differences were found between the effectiveness of tinnitus masking and the affected side, gender, presence of SHL. The higher tinnitus pitch (above 12 kHz) was more common in younger patients and was associated with less successful masking. Conclusion. Our study included patients of predominantly young age (up to 48 years old), in whom, probably, the factors influencing the tinnitus characteristic differ and have a correlation with anxiety-depressive spectrum disorders prevailing at a younger age. In this regard, further research is needed.
- 23 April 2024
- Published by Media Sphere Publishing Group in Russian Bulletin of Otorhinolaryngology
- Vol. 89 (5) , 4-9
Tinnitus features and masking in patients with normal hearing and with high frequency hearing loss
Objective. To access tinnitus features and effectiveness of its masking in relation to sensorineural hearing loss (SHL), gender, age, affected side and tinnitus pitch. Material and methods. 53 patients (32 (60.4%) females and 21 (39.6%) males) aged 20 to 46 years with unilateral chronic tinnitus without any external or middle ear pathology were enrolled in the study. All patients underwent pure tone audiometry, evaluating SHL, tinnitus pitch and tinnitus masking. Pure-tone thresholds were measured at all standard frequencies from 0.25 to 8 kHz, and at 10 kHz, 12.5 kHz, 14 kHz, 16 kHz, and 20 kHz. Results. Normal hearing at the studied frequencies was observed in 24 patients, and 29 patients were found to have SHL. Patients with high-frequency SHL identified tinnitus pitch more often identified tinnitus pitch compared to those with normal hearing (75.9% vs. 45%, respectively; p=0.02). Tinnitus pitch in patients with normal hearing was 8 (6-13) kHz, whereas in all patients with SHL tinnitus pitch was always located in the range of maximum hearing loss and reached 10 (8-12) kHz. The mean tinnitus pitch, which was successfully masked, was 8 Hz, and tinnitus pitches with mean value above 12 kHz were not associated with effective masking (p=0.04). No statistically significant differences were found between the effectiveness of tinnitus masking and the affected side, gender, presence of SHL. The higher tinnitus pitch (above 12 kHz) was more common in younger patients and was associated with less successful masking. Conclusion. Our study included patients of predominantly young age (up to 48 years old), in whom, probably, the factors influencing the tinnitus characteristic differ and have a correlation with anxiety-depressive spectrum disorders prevailing at a younger age. In this regard, further research is needed.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (4) , 48-54
Nocturia in Parkinson’s disease
OBJECTIVE Evaluation of nocturia and its relationship with clinical characteristics of Parkinson’s disease (PD) and dopaminergic therapy. MATERIAL AND METHODS One hundred and thirteen patients with PD of I-III Hoehn and Yahr stage (H&Y) were examined using the following scales: IPSS, including nocturia domain, UPDRS, Sch&En, PDQ-39, MMSE, FAB, BDI, STAI-S and STAI-T, PFS-16, NMSQuest, GDSS, GSRS, and orthotest. RESULTS Nocturia was detected in 93 patients. It depended on the age of the patients (rS=0.345; pp=0.002). We obtained positive correlations of nocturia (p<0.05) with: PDQ-39 (rS=0.296), H&Y (rS=0.223), UPDRS (rS=0.265) and its items (speech, walking disorders, standing up from chair, posture and postural stability), NMSQ (rS=0.318), FAB (rS= –0.359), BDI, STAI-S and STAI-T, PFS-16, gastrointestinal parameters and blood pressure in the supine position. No significant effect of dopaminergic therapy on the severity of nocturia was found. According to regression analysis (stepwise method), predictors of nocturia are depression, higher lying blood pressure, constipation and postural instability (R2=0.474). CONCLUSIONS Nocturia is the most common urological symptom in patients with PD and it significantly reduces the quality of life starting from the early stages of the disease. Nocturia increases as PD progresses, it is independent of dopaminergic medications, and it is directly associated with a number of parkinsonian symptoms (postural, frontal cognitive, affective and autonomic), which are partly dopamine-resistant. This indicates the common pathogenesis of nocturia and other symptoms of PD and the significant influence of polytransmitter imbalance.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (4) , 48-54
Nocturia in Parkinson’s disease
OBJECTIVE Evaluation of nocturia and its relationship with clinical characteristics of Parkinson’s disease (PD) and dopaminergic therapy. MATERIAL AND METHODS One hundred and thirteen patients with PD of I-III Hoehn and Yahr stage (H&Y) were examined using the following scales: IPSS, including nocturia domain, UPDRS, Sch&En, PDQ-39, MMSE, FAB, BDI, STAI-S and STAI-T, PFS-16, NMSQuest, GDSS, GSRS, and orthotest. RESULTS Nocturia was detected in 93 patients. It depended on the age of the patients (rS=0.345; pp=0.002). We obtained positive correlations of nocturia (p<0.05) with: PDQ-39 (rS=0.296), H&Y (rS=0.223), UPDRS (rS=0.265) and its items (speech, walking disorders, standing up from chair, posture and postural stability), NMSQ (rS=0.318), FAB (rS= –0.359), BDI, STAI-S and STAI-T, PFS-16, gastrointestinal parameters and blood pressure in the supine position. No significant effect of dopaminergic therapy on the severity of nocturia was found. According to regression analysis (stepwise method), predictors of nocturia are depression, higher lying blood pressure, constipation and postural instability (R2=0.474). CONCLUSIONS Nocturia is the most common urological symptom in patients with PD and it significantly reduces the quality of life starting from the early stages of the disease. Nocturia increases as PD progresses, it is independent of dopaminergic medications, and it is directly associated with a number of parkinsonian symptoms (postural, frontal cognitive, affective and autonomic), which are partly dopamine-resistant. This indicates the common pathogenesis of nocturia and other symptoms of PD and the significant influence of polytransmitter imbalance.
- 26 December 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (12) , 42-49
Lower gastrointestinal dysfunction in patients with Parkinson’s disease
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценка дисфункции нижних отделов желудочно-кишечного тракта (ЖКТ) и определение ее связи с моторными и немоторными симптомами болезни Паркинсона (БП). МАТЕРИАЛ И МЕТОДЫ Обследованы 118 пациентов с БП I—III ст. по шкале Хен и Яра (H&Y) с применением: UPDRS I—IV, шкалы повседневной активности (Sch&En), качества жизни (PDQ-39), оценки психического статуса (MMSE), депрессии Бека, тревоги Спилбергера, утомляемости (PFS-16), немоторных симптомов (NMSQ), тяжести диспепсии (GDSS), желудочно-кишечных симптомов (GSRS) с доменами, оценивающими диарею и запоры, Бристольской шкалы формы кала, опросника урологических симптомов (AUA), индекса массы тела, измерения слюны и слезы (тест Ширмера). РЕЗУЛЬТАТЫ Запоры присутствовали у 71,2% пациентов, в основном имели легкую—умеренную выраженность; диарея преимущественно легкой степени встречалась у 27,9%, чередование диареи и затруднения опорожнения кишечника — у 25,4%. Выявлены значимые корреляции запоров со шкалами Sch&En (rS=–0,291) и PDQ-39 (rS=0,478), возрастом (rS=0,275), стадией H&Y (rS=0,260), UPDRS (rS=0,254), двигательными аксиальными симптомами паркинсонизма и рядом аффективных и вегетативных расстройств, многие из которых являются отчасти дофаминорезистентными. Диарея не влияла на качество жизни пациентов, не зависела от возраста, стадии БП, основных дигательных и немоторных симптомов, однако прямо коррелировала с тяжестью запоров (rS=0,263) и других расстройств ЖКТ. В нашей когорте пациентов не обнаружено влияния дофаминергической терапии (леводопа, агонисты дофаминовых рецепторов, амантадин) на дисфункцию нижнего отдела ЖКТ. ЗАКЛЮЧЕНИЕ Дисфункция нижнего отдела ЖКТ преимущественно легкой—умеренной тяжести выявляется у большинства пациентов с I—III ст. БП. Полученные нами данные указывают на сложный патогенез нарушения опорожнения кишечника при БП с участием дегенерации недофаминергических структур; а также на преимущественное влияние сопутствующих заболеваний и неадекватной терапии слабительными препаратами на формирование синдрома диареи при БП.
- 26 December 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (12) , 42-49
Lower gastrointestinal dysfunction in patients with Parkinson’s disease
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценка дисфункции нижних отделов желудочно-кишечного тракта (ЖКТ) и определение ее связи с моторными и немоторными симптомами болезни Паркинсона (БП). МАТЕРИАЛ И МЕТОДЫ Обследованы 118 пациентов с БП I—III ст. по шкале Хен и Яра (H&Y) с применением: UPDRS I—IV, шкалы повседневной активности (Sch&En), качества жизни (PDQ-39), оценки психического статуса (MMSE), депрессии Бека, тревоги Спилбергера, утомляемости (PFS-16), немоторных симптомов (NMSQ), тяжести диспепсии (GDSS), желудочно-кишечных симптомов (GSRS) с доменами, оценивающими диарею и запоры, Бристольской шкалы формы кала, опросника урологических симптомов (AUA), индекса массы тела, измерения слюны и слезы (тест Ширмера). РЕЗУЛЬТАТЫ Запоры присутствовали у 71,2% пациентов, в основном имели легкую—умеренную выраженность; диарея преимущественно легкой степени встречалась у 27,9%, чередование диареи и затруднения опорожнения кишечника — у 25,4%. Выявлены значимые корреляции запоров со шкалами Sch&En (rS=–0,291) и PDQ-39 (rS=0,478), возрастом (rS=0,275), стадией H&Y (rS=0,260), UPDRS (rS=0,254), двигательными аксиальными симптомами паркинсонизма и рядом аффективных и вегетативных расстройств, многие из которых являются отчасти дофаминорезистентными. Диарея не влияла на качество жизни пациентов, не зависела от возраста, стадии БП, основных дигательных и немоторных симптомов, однако прямо коррелировала с тяжестью запоров (rS=0,263) и других расстройств ЖКТ. В нашей когорте пациентов не обнаружено влияния дофаминергической терапии (леводопа, агонисты дофаминовых рецепторов, амантадин) на дисфункцию нижнего отдела ЖКТ. ЗАКЛЮЧЕНИЕ Дисфункция нижнего отдела ЖКТ преимущественно легкой—умеренной тяжести выявляется у большинства пациентов с I—III ст. БП. Полученные нами данные указывают на сложный патогенез нарушения опорожнения кишечника при БП с участием дегенерации недофаминергических структур; а также на преимущественное влияние сопутствующих заболеваний и неадекватной терапии слабительными препаратами на формирование синдрома диареи при БП.
- Open Access
- 16 December 2023
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 15 (6) , 32-39
Effect of dopaminergic therapy on lacrimation in Parkinson's disease
The prevalence of dry eye syndrome (DES) in Parkinson's disease (PD) reaches 87% and leads to impaired quality of life in many patients.Objective: to evaluate the lacrimal function and the effect of dopaminergic therapy in patients with PD.Material and methods: 43 patients with stage II–III PD according to Hoehn and Yahr (H&Y) receiving therapy with levodopa (n=17), amantadines (n=13) and dopamine receptor agonists (ADR) (n=28) were assessed using Schirmer's test (to estimate tear flow), sialometry, Unified Parkinson's Disease Rating Scale (UPDRSI-IV), Schwab and England Activities of Daily Living scale (Sch&En), the Parkinson’s Disease Questionnaire Summary Index (PDQ-39), the Mini Mental State Examination Scale (MMSE), the Non-Motor Symptom Questionnaire (NMSQ), the American Urological Association Symptom Scale (AUA), the Gastrointestinal Symptom Rating Scale (GSRS), the Bristol Stool Form Scale (BSFS).Results. Lacrimal insufficiency was found in 49% of patients. It occurred more frequently (χ2=9.546; p=0.003) in patients taking amantadine and correlated with the daily dose of amantadine (r-S=-0.359). It did not depend on the intake of ADR and levodopa and their doses but correlated with the UPDRS-IV score (r-S= -0.463), namely with the presence and duration of OFF-periods. Lacrimal insufficiency correlated with the Sch&En score (r-S=0.321) and non-motor parameters: UPDRSI (r-S =-0.302), NMSQ (r-S=-0.435), constipation domain of the GSRS (r-S=-0.362), BSFS (r-S=0.363). It was not related to age, gender, stage and duration of PD, motor symptoms of parkinsonism (assessed during the ON-phase) and was not related to salivation (although it was reduced in 39.5% of patients).Conclusion. Lacrimal insufficiency is observed in half of patients with stage II–III PD; it is related to the presence and duration of OFF-periods, the severity of other autonomic disorders and the use of amantadines, suggesting the role of dopamine dysregulation, neurodegeneration of autonomic centers and anticholinergic therapy in the development of DES in PD.
- 16 December 2023
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 15 (6) , 32-39
Open AccessEffect of dopaminergic therapy on lacrimation in Parkinson's disease
The prevalence of dry eye syndrome (DES) in Parkinson's disease (PD) reaches 87% and leads to impaired quality of life in many patients.Objective: to evaluate the lacrimal function and the effect of dopaminergic therapy in patients with PD.Material and methods: 43 patients with stage II–III PD according to Hoehn and Yahr (H&Y) receiving therapy with levodopa (n=17), amantadines (n=13) and dopamine receptor agonists (ADR) (n=28) were assessed using Schirmer's test (to estimate tear flow), sialometry, Unified Parkinson's Disease Rating Scale (UPDRSI-IV), Schwab and England Activities of Daily Living scale (Sch&En), the Parkinson’s Disease Questionnaire Summary Index (PDQ-39), the Mini Mental State Examination Scale (MMSE), the Non-Motor Symptom Questionnaire (NMSQ), the American Urological Association Symptom Scale (AUA), the Gastrointestinal Symptom Rating Scale (GSRS), the Bristol Stool Form Scale (BSFS).Results. Lacrimal insufficiency was found in 49% of patients. It occurred more frequently (χ2=9.546; p=0.003) in patients taking amantadine and correlated with the daily dose of amantadine (r-S=-0.359). It did not depend on the intake of ADR and levodopa and their doses but correlated with the UPDRS-IV score (r-S= -0.463), namely with the presence and duration of OFF-periods. Lacrimal insufficiency correlated with the Sch&En score (r-S=0.321) and non-motor parameters: UPDRSI (r-S =-0.302), NMSQ (r-S=-0.435), constipation domain of the GSRS (r-S=-0.362), BSFS (r-S=0.363). It was not related to age, gender, stage and duration of PD, motor symptoms of parkinsonism (assessed during the ON-phase) and was not related to salivation (although it was reduced in 39.5% of patients).Conclusion. Lacrimal insufficiency is observed in half of patients with stage II–III PD; it is related to the presence and duration of OFF-periods, the severity of other autonomic disorders and the use of amantadines, suggesting the role of dopamine dysregulation, neurodegeneration of autonomic centers and anticholinergic therapy in the development of DES in PD.